BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Dec 19, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Exjade deferasirox: Phase II data

Additional data from the double-blind, international, pivotal Phase II THALASSA trial in 166 patients showed that once-daily 10 mg/kg Exjade reduced liver iron concentration, the primary endpoint, by 3.8 mg of iron per gram of liver dry weight from baseline to 1 year vs. an increase of 0.38 mg of iron per gram of liver dry weight for placebo (p<0.001)....

Read the full 280 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >